What's in FutureGen Biopharmaceutical (Beijing) Co., Ltd's pipeline?

FutureGen Biopharmaceutical (Beijing) Co., Ltd has 4 drugs in our index: 0 marketed, 0 filed, 3 in Phase 3, 0 in Phase 2, 1 in Phase 1.

Which companies overlap with FutureGen Biopharmaceutical (Beijing) Co., Ltd's portfolio?

No competitive overlap detected.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/futuregen-biopharmaceutical-beijing-co-ltd.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-17 · How we verify

FutureGen Biopharmaceutical (Beijing) Co., Ltd — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

FutureGen Biopharmaceutical (Beijing) Co., Ltd pipeline: 0 marketed, 0 filed, 3 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 3 Phase 3 0 Phase 2 1 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Area
M108 monoclonal antibody	M108 monoclonal antibody	phase 3	Oncology
FG-M108	FG-M108	phase 3	Oncology
Placebo for FG-M108	Placebo for FG-M108	phase 3

Therapeutic area mix

Oncology · 2

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

No competitive overlap data.

Subscribe to ongoing alerts

Every new pipeline event for FutureGen Biopharmaceutical (Beijing) Co., Ltd:

Cite this brief

Drug Landscape (2026). FutureGen Biopharmaceutical (Beijing) Co., Ltd — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/futuregen-biopharmaceutical-beijing-co-ltd. Accessed 2026-05-17.